MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

P. Goetz, Matthew; Toi, Masakazu; Campone, Mario; Sohn, Joohyuk; Paluch–Shimon, Shani; Huober, Jens; Hae Park, In; Trédan, Olivier; Chen, Shin‐Cheh; Manso, Luís; Freedman, Orit; Garnica Jaliffe, Georgina; Forrester, Tammy; Frenzel, Martin; Barriga, Susana; C. P. Smith, Ian; Bourayou, Nawel; Di Leo, Angelo

doi:10.1200/jco.2017.75.6155

Public

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Published in Journal of Clinical Oncology • Oct 2, 2017

Authors:

Matthew P. Goetz

Masakazu Toi

Mario Campone

Abstract

Purpose Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, demonstrated efficacy as monotherapy and in combination with fulvestrant in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with endocrine t...

Subject

Medicine

Internal medicine

Fulvestrant

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!